SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34991813.
- Also identified by DOI 10.1016/j.kint.2021.10.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are known to slow down progression of chronic kidney disease. However, theoretical concerns still exist that SGLT2 inhibitors could increase the risk of acute kidney injury. Heerspink et al. revealed that dapagliflozin, an SGLT2 inhibitor, reduced the risk of abrupt declines in kidney function during the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial. Their findings may serve to reassure clinicians prescribing SGLT2 inhibitors to patients with chronic kidney disease.
Medical subject headings
- Acute Kidney Injury
- Diabetes Mellitus, Type 2
- Renal Insufficiency, Chronic
- Sodium-Glucose Transporter 2 Inhibitors